Streetbeat News

Price Targets

ONEXF

CIBC analyst Nik Priebe upgraded Onex (OTC:ONEXF) from Neutral to Outperformer and raised the price target from $70 to $88.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 5:05 pm

AEL

In the last quarter, American Equity Inv (NYSE:AEL) received 1 bullish, 2 somewhat bullish, and 4 indifferent ratings from analysts. The average 12-month price target for AEL is $45.71, with a high of $50.00 and a low of $39.00, increasing by 6.3% over the past month.

Portfolio Pulse from Benzinga Insights

June 09, 2023 | 5:03 pm

PFG

Keefe, Bruyette & Woods upgraded its rating of Principal Financial Group (NASDAQ:PFG) to Market Perform with a price target of $75.00, down from $77.00. Shares of PFG are trading up 0.49% over the last 24 hours, at $71.17 per share.

Portfolio Pulse from Benzinga Insights

June 09, 2023 | 5:02 pm

MTB

In the last quarter, M&T Bank (NYSE:MTB) received 4 bullish, 3 somewhat bullish, and 4 indifferent analyst ratings. The average 12-month price target for the company is $151.64, down 6.45% from the previous average of $162.10.

Portfolio Pulse from Benzinga Insights

June 09, 2023 | 5:02 pm

CC

RBC Capital has maintained its Sector Perform rating for Chemours (NYSE:CC) and raised its price target from $36.00 to $37.00. Shares of Chemours are currently trading down 3.21% at $31.94 per share.

Portfolio Pulse from Benzinga Insights

June 09, 2023 | 5:01 pm

BRZE

UBS maintains its Neutral rating for Braze (NASDAQ:BRZE) and raises its price target from $35.00 to $38.00. Shares of Braze are trading up 18.47% over the last 24 hours, at $40.21 per share.

Portfolio Pulse from Benzinga Insights

June 09, 2023 | 5:00 pm

ZWS

Oppenheimer has maintained its Outperform rating for Zurn Elkay Water (NYSE:ZWS) and raised its price target from $27.00 to $29.00. ZWS shares are trading up 0.57% at $25.75 per share.

Portfolio Pulse from Benzinga Insights

June 09, 2023 | 5:00 pm

IRON

Raymond James analyst Danielle Brill upgrades Disc Medicine (NASDAQ:IRON) from Outperform to Strong Buy and raises the price target from $50 to $75.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 4:58 pm

CRSP

Needham analyst Gil Blum has reiterated a Buy rating on CRISPR Therapeutics (NASDAQ:CRSP) and raised the price target from $82 to $88.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 4:57 pm

DOCU

Citigroup analyst Tyler Radke reiterated a Buy rating on DocuSign (NASDAQ: DOCU) and raised the price target from $73 to $78.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 4:52 pm